Ridgeback Biotherapeutics


Ridgeback Biotherapeutics is a privately held company which focuses on developing therapies and diagnostic tests for pediatric orphan and infectious diseases.  We fund research and develop technologies in diseases that are typically below the radar of conventional large biotechnology and pharmaceutical companies.  We focus on diseases that need champions.  It is our goal and the goal of our collaborators to advance treatments and diagnostics that make a difference.

PRNewswire: Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases